Sanofi: Diverse Drug Portfolio & Future Pipeline, 4% Dividend …
5 hours ago · A major news story from Sanofi this month is that "The European Medicines Agency has approved Dupixent (dupilumab) to treat eosinophilic esophagitis (EoE) in children as young as one year of age."
Healx announces agreement with Sanofi to seek new rare disease ...
16 hours ago · CAMBRIDGE, England, November 13, 2024--Healx, an AI-enabled, clinical-stage biotech company specialising in rare diseases, today announced it will use a Sanofi compound to identify new disease ...
Sanofi/Regeneron Pharmaceuticals' DUPIXENT Approval Marks a …
17 hours ago · Sanofi/Regeneron Pharmaceuticals' DUPIXENT Approval Marks a Significant Shift in Chronic Obstructive Pulmonary Disease Treatment Landscape | DelveInsight PR Newswire Tue, Nov 12, 2024, 5:31 PM 10 ...
Sanofi Cancels Consumer Healthcare Business Spin-Off - Forbes
Oct 30, 2024 · Sanofi’s decision to cancel the spin-off of its consumer healthcare business and go ahead with a sell a 50% stake to CD&R reflects a strategic shift aimed at focusing more on its core ...
Sanofi Earns $5B Q3 Core Profit On Strong Dupixent And Vaccine …
On Friday, Sanofi SA (NASDAQ: SNY) reported a third-quarter business operating income of 4.61 billion euros ($4.99 billion), up 14.4% year-over-year and 19.9% in constant currency. The company ...
Sanofi US News
Sep 27, 2024 · Sanofi and Regeneron are motivated to transform the treatment paradigm of COPD by examining the role different types of inflammation play in the disease progression through Dupixent, a first-in-class biologic, and the investigation of itepekimab.
Sanofi pushes ahead with €20bn consumer healthcare spin-off
Jun 2, 2024 · The move makes Sanofi the latest Big Pharma company to seek to separate low-margin, consumer businesses from divisions focused on innovative new medicines that offer higher returns.
Press Room - Sanofi US News
Oct 16, 2024 · FLUBLOK® (Influenza Vaccine) US label updated with one of Sanofi's largest flu vaccine safety studies in pregnant individuals. Read more.
Press Room - Sanofi US News
Updated as of October 26, 2023. There has been unprecedented demand for Beyfortus™ (nirsevimab-alip). For the first time in history, health care providers are able to help protect an extraordinary number of infants against respiratory syncytial virus (RSV) disease.
Sanofi BTK inhibitor for blood disease raises platelet levels
Nov 5, 2024 · Sanofi has released phase 3 data from the LUNA 3 trial of rilzabrutinib that should spark some buyer’s delight. The drug, which the French pharma giant acquired through a $3.7 billion buyout of ...
- Some results have been removed